eligibility_summary
Adults with R/R DLBCL (incl PMBCL, transformed FL), no response to last therapy or SD ≤6 mo, ineligible or refractory to ASCT, ≥2 prior lines incl anthracycline, double/triple‑hit after 2L failure, CD19+, measurable disease, ECOG 0–1, LVEF ≥45%, adequate organs, >12‑wk survival, AEs recovered, washouts, contraception. Exclude: CNS disease, allo‑HSCT, recent chemo/other trial, active HBV/HCV/HIV/syphilis or infection, recent MI/UA, other malignancy, pregnancy, neuroautoimmune.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Meta10-19, an autologous, gene‑modified CD19‑directed CAR‑T cell therapy (“metabolically armed”). Mechanism: CAR recognition of CD19 triggers T‑cell activation and cytotoxic killing of CD19+ lymphoma cells. The “metabolic armoring” is designed to enhance T‑cell metabolic fitness within the tumor microenvironment, improving expansion, persistence, and function. Preconditioning: Cyclophosphamide (alkylating agent) and fludarabine (purine analog) are given for lymphodepletion to facilitate CAR‑T engraftment. Targets: CD19 on malignant (and normal) B cells in r/r DLBCL, engages CAR signaling pathways (CD3ζ/co‑stimulation) in T cells and leverages T‑cell metabolic pathways, lymphodepletion targets host lymphocytes/cytokine sinks.